Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- T cells and oncology
- Therapeutic use T cells
- Therapeutic use of gene engeneered T cells (1)
- Chimeric Antigen Receptors (CAR)
- Anti-CD19 CAR T cells: clinical responses (1)
- Anti-CD19 CAR T cells: clinical responses (2)
- Anti-CD19 CAR T cells: clinical responses in diffuse large B cell lymphoma
- Successful treatment with CAR T cells
- F.D.A. approved treatment
- Toxicities associated with CAR T cell therapy: Cytokine Release Syndrom (CRS)
- Therapeutic use of gene engeneered T cells (2)
- Therapeutic use of T cells: TCR vs. CAR (1)
- Therapeutic use of T cells: TCR vs. CAR (2)
- TCR vs. CAR: advantages and disadvantages
- TCR vs. CAR: mode of action
- Common effector molecules for CAR and TCR T cells
- Issues associated with anti-CD19-CAR T cell therapies
- Limited applicability of CAR T cells outside of hematological malignancies so far
- The bottlenecks to CAR T cell therapy efficacy in solid tumors
- Potential solutions - by means of engineering
- Acknowledgements
- Disclosures
Topics Covered
- Introduction to therapeutic use T cells
- Clinical use of CAR T cell therapy
- The mode of action of CAR T cell therapy
- Differences to TCR T cell therapy
- Resistance mechanisms to CAR T cell therapy
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Kobold, S. (2020, November 30). Mode of action of T cells engineered with CAR or TCR for cancer treatment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/XFDK9879.Export Citation (RIS)
Publication History
Financial Disclosures
- Sebastian Kobold (S.K.) has licensed IP to TCR2 Inc, Boston. S.K. has received research support from TCR2 Inc and Arcus Biosciences. S.K. serves on the scientific advisory board of TCR2 Inc and on various scientific advisory boards of Novartis.
Mode of action of T cells engineered with CAR or TCR for cancer treatment
Published on November 30, 2020
36 min
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hi. My name is Sebastian Kobold,
I'm a Professor of Medicine and Experimental Immuno-oncology and
Vice-Chair of Clinical Pharmacology here at
the University Hospitals of Ludwig Maximilians University in Munich.
Today, I want to tell you more about how T cells that have been engineered,
either with a chimeric antigen receptor or with
a T cell receptor work for cancer treatment.
I would just go straight ahead with saying that most of the talk will be
about chimeric antigen receptors CAR because they're
the so far only approved treatment or cellular treatment for cancer that we have and
that's why I think it's much more important to focus on those
than on the TCRs which are currently more experimental.
0:46
T cells are really at the core of therapeutic developments in oncology and the reason for
that is really being because it has been recognized that T cells are being hampered,
are being suppressed by cancer cells in
order to give the cancer cells the opportunity to grow and to progress.
Meaning that in a sense,
T cells have the natural ability to become
specific against specific or cancer associated antigens.
But the issue is that T cells are being suppressed by
the tumor cell to allow the tumor cell freedom to grow and to metastasize.
But it has been recognized that in this sense,
two molecules seem to be very important to suppress T cell activity and cancer,
which is the programmed death receptor1 and a cytotoxic T lymphocyte antigen-4, CTLA-4.
One of the big part of the advances in oncology in recent years has been
that if you block either of those pathways by, let's say,
monoclonal antibodies as depicted on the slide,
you can actually reinvigorate T cell responses and
enable them to recognize cancer cells again.
This has been really a paradigm shift in oncology because now for the first time,
we really had a drug or a modality that's not targeting the cancer cell at all,
but really targeting only immune cells or T cells in this case.
By doing so, they re-enable the immune system to
recognize cancer cells and to be therapeutic.
In a sense, T cells have become really premium or prime anti-cancer weapons.
At the core of this recognition stems the following idea,
Hide